0001209191-18-001383.txt : 20180103
0001209191-18-001383.hdr.sgml : 20180103
20180103185902
ACCESSION NUMBER: 0001209191-18-001383
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20171229
FILED AS OF DATE: 20180103
DATE AS OF CHANGE: 20180103
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: SCHAFER GREGORY W
CENTRAL INDEX KEY: 0001193195
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37345
FILM NUMBER: 18507708
MAIL ADDRESS:
STREET 1: C/O CERUS CORP
STREET 2: 2411 STENWELL DRIVE
CITY: CONCORD
STATE: CA
ZIP: 94520
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: ADURO BIOTECH, INC.
CENTRAL INDEX KEY: 0001435049
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 740 HEINZ AVENUE
CITY: BERKELEY
STATE: CA
ZIP: 94710
BUSINESS PHONE: 510-848-4400
MAIL ADDRESS:
STREET 1: 740 HEINZ AVENUE
CITY: BERKELEY
STATE: CA
ZIP: 94710
FORMER COMPANY:
FORMER CONFORMED NAME: ADURO BIOTECH
DATE OF NAME CHANGE: 20080514
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2017-12-29
0
0001435049
ADURO BIOTECH, INC.
ADRO
0001193195
SCHAFER GREGORY W
C/O ADURO BIOTECH, INC.
740 HEINZ AVENUE
BERKELEY
CA
94710
0
1
0
0
Chief Operating Officer
Common Stock
2017-12-29
4
M
0
42000
0.82
A
190745
D
Common Stock
2018-01-02
4
M
0
13068
0.82
A
203813
D
Common Stock
2018-01-02
4
M
0
6932
1.45
A
210745
D
Common Stock
2018-01-02
4
S
0
20000
7.6071
D
190745
D
Stock Option (right to buy)
0.82
2017-12-29
4
M
0
42000
0.00
D
2023-11-26
Common Stock
42000
160390
D
Stock Option (right to buy)
0.82
2018-01-02
4
M
0
13068
0.00
D
2023-11-26
Common Stock
13068
147322
D
Stock Option (right to buy)
1.45
2018-01-02
4
M
0
6932
0.00
D
2025-01-09
Common Stock
6932
92813
D
The sales reported in this Form 4 were affected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 24, 2017.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.45 to $7.73, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
The shares subject to the Option became fully vested and exercisable as of July 1, 2017.
The shares subject to the Option vest in 48 equal monthly installments from the vesting commencement date of January 10, 2015.
/s/ Jennifer Lew, Attorney-in-Fact
2018-01-03